研究業績

論文・出版

Switch maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial


Shigehira Saji, Naruto Taira, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Tohru Ohtake, Tatsuya Toyama, Yuichiro Kikawa, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba,, Takanori Ishida,Rikiya Nakamura, Yutaka Yamamoto, Uhi Toh, Hiroji Iwata, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi


Lancet Oncol . 2022 May;23(5):636-649


doi: 10.1016/S1470-2045(22)00196-6.

Immune microenvironment, homologous recombination deficiency and therapeutic response to neoadjuvant chemotherapy in triple negative breast cancer : Japan Breast Cancer Research Group (JBCRG)22 TR


Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravindranath M. Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi


BMC Medicine 2022 Apr 25;20(1):136.


doi: 10.1186/s12916-022-02332-1.

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative breast cancer: An ad-hoc analysis of the JBCRG-C06 Safari study


Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno


Japanese Journal of Clinical Oncology, 2022


https://doi.org/10.21203/rs.3.rs-190374/v1

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)


Ippei Fukada, Yoshinori Ito, Naoto Kondo, Shoichiro Ohtani, Masaya Hattori, Eriko Tokunaga, Nobuki Matsunami, Kohjiro Mashino, Taijiro Kosaka, Masahiko Tanabe, Daisuke Yotsumoto, Kosho Yamanouchi, Masataka Sawaki, Masahiro Kashiwaba, Hidetaka Kawabata, Katsumasa Kuroi, Satoshi Morita, Shinji Ohno, Masakazu Toi, Norikazu Masuda


Breast Cancer Research and Treatment, 2021 190, 425–434


https://doi.org/10.1007/s10549-021-06396-0

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)


Eriko Tokunaga, Norikazu Masuda, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando, Tomoyuki Aruga, Shoichiro Ohtani, Tomomi Fujisawa, Toshimi Takano, Kenichi Inoue, Nobuyasu Suganuma, Masahiro Takada, Kenjiro Aogi, Kenichi Sakurai, Hideo Shigematsu, Katsumasa Kuroi, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi


Cancers 2021 August, 13(16), 4008


https://doi.org/10.3390/cancers13164008

Meta‑analysis of nanoparticle albumin‑bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG‑S01 study)


Manabu Futamura, Mari Oba, Norikazu Masuda, Hiroko Bando, Morihito Okada, Yutaka Yamamoto, Takanori Kin, Toshiaki Saeki, Takeshi Nagashima, Takashi Kuwayama, Uhi Toh, Akira Hirano, Masafumi Inokuchi, Kazuhiko Yamagami, Yutaka Mizuno, Yasuyuki Kojima, Takahiro Nakayama, Hiroyuki Yasojima, Shinji Ohno


Breast Cancer 28, 2021 April, 1023–1037


https://doi.org/10.1007/s12282-021-01238-9

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)


Kenjiro Aogi, Kenichi Watanabe, Masahiro Kitada, Takafumi Sangai, Shoichiro Ohtani, Tomoyuki Aruga, Hidetoshi Kawaguchi, Tomomi Fujisawa, Shigeto Maeda, Takashi Morimoto, Nobuaki Sato, Shintaro Takao, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Shinji Ohno


International Journal of Clinical Oncology 2021 April, 26:1229–1236


https://doi.org/10.1007/s10147-021-01920-0

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial (JBCRG-22)


Norikazu Masuda, Hiroko Bando, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita, Hironori Haga, Tatsuki R. Kataoka, Ryuji Uozumi, Shinji Ohno, Masakazu Toi


Breast Cancer Research and Treatment , 2021 March, 188: 117–131


https://doi: 10.1007/s10549-021-06184-w

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: A multicenter, single arm, phase II study (JBCRG-M03 study)


Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M


Invest New Drugs. ;39(1):217-225(2021)


doi: 10.1007/s10637-020-00991-6

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study


Yutaka Yamamoto, Hiroyasu Yamashiro, Uhi Toh, Naoto Kondo, Rikiya Nakamura, Masahiro Kashiwaba, Masato Takahashi, Koichiro Tsugawa, Takashi Ishikawa, Takahiro Nakayama, Shoichiro Ohtani, Toshimi Takano, Tomomi Fujisawa, Tatsuya Toyama, Hidetoshi Kawaguchi, Kojiro Mashino, Yuichi Tanino, Satoshi Morita, Masakazu Toi, Shinji Ohno


Breast Cancer 2021 Jan; 28(1):145-160


https://doi.org/10.1007/s12282-020-01138-4

次のページへ
任意団体JBCRG 研究業績